Gestational diabetes & diabetes in pregnancy
Use of commercially available automated insulin delivery systems in pregnant people with type 1 diabetes
Main finding · Mean antenatal TIRResult — go to the resultAdjusted mean difference 7.9 % 95% CI 0.8–15.0Authors' conclusion
In this real-world study, off-label AID use during pregnancy improved TIR while decreasing TBR. While awaiting commercially available AIDs with pregnancy algorithms, standardized approaches to optimizing current systems are needed.
Study context
- Population
- Pregnant people with T1D who used continuous glucose monitor (CGM) during pregnancy
- Participants
- 38 people
- Exposure
- Automated insulin delivery (AID) vs standard of care
- AIDn = 21
- Standard of caren = 17reference
- Outcome
- Time in range (TIR)
- Follow-up
- Mean antenatal
Methodological detailsreal-world, off-label AID use
- Real-world
- Off-label AID use
Main finding
Mean antenatal TIR
Adjusted mean difference
7.9 %
95% CI 0.8–15.0
P = 0.03
By group
AID
68.5
mean · SD 12.9 · %
AIDvs Standard of care
adjusted mean difference 7.9 % (95% CI 0.8–15.0); P = 0.03
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
TBR · lower with AID
P = 0.03
| Outcome | AID | Standard of care | P value |
|---|---|---|---|
| Glucose SDLower with AID | 37.2 ± 8.0 | 45.5 ± 8.9 | P = 0.02 |
Original publication
Use of commercially available automated insulin delivery systems in pregnant people with type 1 diabetes. Diabetes Res Clin Pract. Published 1 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →